01—Abstract
Summary
Summary of the 10-K filed March 28, 1996. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation's 1995 10-K shows a company in strong growth, with net sales up 28% to $871.9 milliona (from $681.9 million) and net earnings up 20% to $87.0 million, or $1.80 per share.
Growth was driven heavily by the August 1994 consolidation of Japanese distributor Matsumoto Medical Instruments (51% owned), which contributed roughly 15 points of sales growth, and by Stryker Surgical products (orthopaedic implants, endoscopy, powered instruments), which rose 21% to $608.6 millionb. International sales reached 45% of revenue, up from 41%. Operating margin improved to 18.0% from 17.7%, although the consolidation of lower-margin distribution revenue diluted SG&A, which rose to 34.6% of sales from 32.5%, and the effective tax rate rose to 41.0% due to Japanese taxes.
The balance sheet remained strong, with cash and marketable securities of $264.6 millionc, working capital of $448.8 million, a current ratio of 3.6, and total debt of about $100 million, mostly yen-denominated bank loans that hedge the Matsumoto investment. Operating cash flow was $111.5 million. Management flagged several watch items: Matsumoto's distributed-products sales fell 29% in Q4 1995 as distribution agreements were terminated and are expected to decline further in 1996; inventory days rose slightly to 133; and the company's OP-1 bone growth device remains in clinical trials with no PMA filed.
Investors should also note a pending court award of $72.7 milliond against Intermedics, which is under appeal and not recognized in the financials. Overall, the filing describes a company with accelerating revenue growth, expanding margins in its core surgical business, a fortress balance sheet, and a few identifiable risks: dependence on international and Japanese operations, a possible drop in distributed-product revenue, and an uncertain appeal of a large contingent gain.
02—Key points
Key Highlights
- Net sales rose 28% to $871.9 million in 1995, and net earnings rose 20% to $87.0 million ($1.80 per share).
- The Matsumoto consolidation (51% stake since August 1994) contributed about 15 points of sales growth, and Matsumoto Distributed Products grew 141% to $104.8 million.
- Stryker Surgical products grew 21% to $608.6 million, led by Osteonics hip and knee implants, and Dimso spinal implants entered the U.S. market in 1995.
- International sales reached 45% of total revenue (up from 41%), making Stryker increasingly dependent on foreign markets, particularly Japan.
- Operating income rose 31% to $157.3 million, with operating margin improving to 18.0% from 17.7%, though SG&A rose to 34.6% of sales from 32.5%.
- The balance sheet is strong: $264.6 million in cash and marketable securities, $448.8 million in working capital, a 3.6 current ratio, and about $100 million in mostly yen-denominated debt.
- A pending $72.7 million patent damage award against Intermedics (under appeal) is not reflected in the financial statements and represents potential upside.
03—Questions
Frequently Asked Questions
What drove Stryker's revenue growth in 1995?
Most of the 28% growth came from consolidating Matsumoto Medical Instruments, the Japanese distributor in which Stryker raised its stake to 51% in August 1994, which added about 15 points of growth. Organic unit volume added 6 points, other acquisitions added 3 points, and currency added 1 point. Stryker Surgical products grew 21%, led by Osteonics implants and the Steri-Shield product line.
Is the margin expansion sustainable?
Gross margin improved because Matsumoto's distribution sales carry higher margins on Stryker products and because of the Osteonics shift to direct hospital sales. However, the consolidation of distributor-style operations raised SG&A to 34.6% of sales, and the effective tax rate increased to 41.0% from 39.8% due to higher Japanese taxes. Margin trends will depend on the mix between Stryker products and lower-margin distributed products, which management expects to decline in 1996.
What risks does the filing highlight for 1996?
Management said sales of Matsumoto Distributed Products fell 29% in Q4 1995 after several distribution agreements were terminated, and expects a further decline in 1996. The company also faces competition from larger rivals such as Zimmer, DePuy, Howmedica, and J&J Professional, as well as health care cost containment pressures. The OP-1 bone growth device remains in clinical trials with no PMA filed, and the company notes that a patent license from competitors may be needed.
What is the Intermedics litigation and how could it affect investors?
In July 1995, a federal court held Stryker's Omniflex hip system patent valid and enforceable against Intermedics Orthopedics and its distributor, and fixed the damage award at $72.7 million including interest. Intermedics has appealed, and management cannot yet determine the financial impact, so no gain has been recorded. If the award is upheld and collected, it would be a material one-time gain relative to 1995 net earnings of $87.0 million, but the outcome is uncertain until the appeal is resolved.
Is Stryker's balance sheet able to fund growth and acquisitions?
Yes. At December 31, 1995, the company had $264.6 million in cash and marketable securities, $448.8 million in working capital, and a current ratio of 3.6. Operating cash flow was $111.5 million, and unused bank lines totaled $55.4 million. Long-term debt of $97.0 million consists mainly of yen-denominated bank loans that hedge the Matsumoto investment and mature in August 1998. Management says these resources are sufficient for operating needs and future acquisitions.
04—Continue